Skip to main content
ILMN
NASDAQ Industrial Applications And Services

Illumina Reports Final Q4 & FY25 Financial Results, Projects Modest Growth for FY26

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$128.8
Mkt Cap
$20.416B
52W Low
$68.7
52W High
$155.529
52W Position info
87% above low
Off High info
17% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ILMN sits 87% above its 52-week low of $68.7.

Summary

Illumina reported final Q4 2025 revenue growth of 5% and flat FY 2025 revenue, while providing FY 2026 guidance projecting 4-6% revenue growth, including contributions from the SomaLogic acquisition.


Key Events · Earnings and Guidance · ILMN

  • Q4 2025 Revenue Growth

    Illumina reported Q4 2025 revenue of $1.16 billion, marking a 5% increase from Q4 2024, indicating a return to growth.

  • Fiscal Year 2025 Performance

    Full fiscal year 2025 revenue was $4.34 billion, remaining flat compared to fiscal year 2024.

  • Fiscal Year 2026 Guidance

    The company provided FY 2026 revenue guidance of $4.5 billion to $4.6 billion, representing 4-6% growth, and non-GAAP diluted EPS in the range of $5.05-$5.20.

  • SomaLogic Acquisition Impact

    The recently completed SomaLogic acquisition is expected to contribute 1.5-2.0% to FY 2026 revenue growth but will dilute non-GAAP diluted EPS by $0.18.


Analysis · ILMN · Industrial Applications And Services

Illumina, Inc. has released its final financial results for the fourth quarter and fiscal year 2025, following a preliminary announcement on January 13, 2026. The company reported a 5% revenue increase for Q4 2025, reaching $1.16 billion, signaling a return to growth. However, full-year 2025 revenue remained flat at $4.34 billion compared to the prior year. For fiscal year 2026, Illumina projects total revenue between $4.5 billion and $4.6 billion, representing 4-6% growth, which includes a 1.5-2.0% benefit from the recently completed SomaLogic acquisition. The acquisition is also expected to dilute non-GAAP diluted EPS by $0.18, with overall non-GAAP EPS guidance set at $5.05-$5.20. This filing provides definitive figures and forward-looking guidance, offering investors a clearer picture of the company's trajectory and the integration impact of its recent acquisition.

At the time of this filing, ILMN was trading at $128.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.4B. The 52-week trading range was $68.70 to $155.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ILMN - Latest Insights

ILMN
Jul 06, 2026, 7:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $189.30
Real-time Price: $192.50 info
Change: +$3.20 (+2%) info
Market Cap: $29.198B info
ILMN
Jun 23, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $158.38
Real-time Price: $192.50 info
Change: +$34.12 (+22%) info
Market Cap: $29.198B info
ILMN
Jun 01, 2026, 6:04 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $164.40
Real-time Price: $192.50 info
Change: +$28.10 (+17%) info
Market Cap: $29.198B info
ILMN
May 29, 2026, 6:14 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $164.88
Real-time Price: $192.50 info
Change: +$27.62 (+17%) info
Market Cap: $29.198B info
ILMN
May 14, 2026, 7:21 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $144.85
Real-time Price: $192.50 info
Change: +$47.65 (+33%) info
Market Cap: $29.198B info